Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) shares dropped 5.9% on Monday . The stock traded as low as $7.40 and last traded at $7.2150. 5,122 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 59,382 shares. The stock had previously closed at $7.67.
Analyst Ratings Changes
Separately, Weiss Ratings cut shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on Anbio Biotechnology
Anbio Biotechnology Trading Down 5.7%
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Further Reading
- Five stocks we like better than Anbio Biotechnology
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
- AST SpaceMobile Is Down 54%—Can FCC Progress and BlueBirds Reverse the Slide?
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
